Sign in Subscribe
Hospitals

AI-Powered Heart Failure Detection Revolutionizes Cardiology

Strategic Insights

— 1 min read

Pioneering cardiology solution, Ultromics, is making waves in the medical industry with its FDA-cleared AI technology that detects heart failure earlier and more accurately than traditional methods. By analyzing routine echocardiograms, Ultromics' EchoGo platform enables clinicians to identify high-risk patients earlier, initiating treatment before disease progression. This breakthrough innovation has already been validated across 25 peer-reviewed studies and is now scaling nationwide, making early heart failure detection a routine part of cardiac care.

Key Takeaways:

  • Ultromics has raised $55 million in Series C financing to expand its AI-powered diagnostic capabilities across the U.S.
  • The company's EchoGo platform is the first FDA-cleared, Medicare-reimbursed AI technology to detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure.
  • Ultromics has analyzed over 430,000 echocardiograms to date, with clinical studies showing an improvement in HFpEF detection by 73.6% compared to standard clinical risk scores.
  • The company's latest diagnostic model for cardiac amyloidosis outperformed current clinical risk scores in a global study of 18 institutions.
  • Ultromics is expanding its pipeline to include additional cardiac conditions, new distribution channels, and deeper partnerships with health systems and clinical leaders.
  • The company's platform is helping hospitals reduce unnecessary tests, streamline workflows, and initiate treatment earlier, reducing healthcare costs.
  • Ultromics has received FDA Breakthrough Device clearance for EchoGo Amyloidosis and launched EchoGo Score, a feature that adds AI-driven probability scoring to EchoGo Heart Failure.

Statistics:

  • Heart failure drives over $30 billion in annual healthcare costs in the U.S., projected to exceed $70 billion by 2030.
  • Up to 64% of heart failure cases still go undetected.
  • Emerald, and, are often missed or delayed diagnoses despite patients actively seeking care.
  • Ultromics' EchoGo platform has been trained and validated on one of the largest real-world echo datasets globally.
  • The platform has been fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide.

Sources:

  • Ultromics' press release, "Ultromics Raises $55 Million in Series C Financing to Expand AI-Powered Diagnostic Capabilities," dated July 31, 2025.
  • Oxford Science Enterprises, Venture Capital, at L&G, press release, "L&G Invests in Ultromics to Transform Cardiovascular Diagnostics."
  • Lightrock, press release, "Lightrock and L&G Partner to Support Ultromics in Developing AI-Driven Diagnostic Solutions."
  • Allegis Capital, press release, "Allegis Capital Invests in Ultromics to Revolutionize Cardiology."

Read more